



## Clinical trial results:

### Conventional ovarian stimulation vs. stimulation with single injection of Corifollitropin alfa in oocyte donors. Randomized clinical trial. Tail Studio

#### Summary

EudraCT number	2019-001343-44
Trial protocol	ES
Global end of trial date	08 May 2021

#### Results information

Result version number	v1 (current)
This version publication date	27 August 2022
First version publication date	27 August 2022
Summary attachment (see zip file)	2019-001343-44 (Tail_results.pdf)

#### Trial information

##### Trial identification

Sponsor protocol code	IB-0319-002
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03939403
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Instituto Bernabeu
Sponsor organisation address	Av. Albufereta 31, Alicante, Spain, 03016
Public contact	Anna Pitas, Instituto Bernabeu, 34 965154000, apitas@institutobernabeu.com
Scientific contact	Anna Pitas, Instituto Bernabeu, 34 965154000, apitas@institutobernabeu.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	16 February 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 March 2021
Global end of trial reached?	Yes
Global end of trial date	08 May 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To study the efficiency of the use of a single injection of CFA for ovarian stimulation, initiating administration late and without further contribution of FSH activity after the 7th day of stimulation compared to conventional EOC using CFA (administration of the drug 5 days after cesar hormonal contraceptive and supplementation with FSH daily administration from the 8th day of stimulation).

Protection of trial subjects:

Measures as per usual clinical practice.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 June 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 180
Worldwide total number of subjects	180
EEA total number of subjects	180

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	180
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Recruitment among the oocyte donors at our clinic.

### Pre-assignment

Screening details:

Completion of the screening criteria, normal ultrasound scan and normal hormonal analysis results.

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	control group

Arm description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:  
The control group receives the treatment on the 5th day after the cessation of hormonal contraceptive use and also receives additional FSH.

Arm type	Active comparator
Investigational medicinal product name	ELONVA
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

SINGLE SUBCUTANEOUS INJECTION, 250 mcg ofcorifolitropine alfa

<b>Arm title</b>	study group
------------------	-------------

Arm description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:  
The intervention group receives the treatment on the 7th day after the cessation of hormonal contraceptive use and does not receive additional FSH.

Arm type	Experimental
Investigational medicinal product name	ELONVA
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:

SINGLE SUBCUTANEOUS INJECTION, 250 mcg ofcorifolitropine alfa

<b>Number of subjects in period 1</b>	control group	study group
Started	90	90
Completed	81	68
Not completed	9	22
Physician decision	9	11
Covid	-	3
Lost to follow-up	-	8

## Baseline characteristics

### Reporting groups

Reporting group title	control group
Reporting group description: The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity: The control group receives the treatment on the 5th day after the cessation of hormonal contraceptive use and also receives additional FSH.	
Reporting group title	study group
Reporting group description: The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity: The intervention group receives the treatment on the 7th day after the cessation of hormonal contraceptive use and does not receive additional FSH.	

Reporting group values	control group	study group	Total
Number of subjects	90	90	180
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: years			
arithmetic mean	24.52	24.52	
standard deviation	± 6.26	± 5.69	-
Gender categorical Units: Subjects			
Female	90	90	180
Male	0	0	0

### Subject analysis sets

Subject analysis set title	Tail
Subject analysis set type	Per protocol
Subject analysis set description: All oocyte donors included in the study were healthy women 18 - 32 years, with body mass index between 18 and 29 kg/m <sup>2</sup> , an antral follicle count (AFC) > 12, both ovaries present, with regular menstrual cycles and recruited according to the clinical and legal requirements of the Spanish Act for Assisted Human Reproduction: Reproductive Act (RD 9/2014) which includes: a psychological interview, gynecological examination and a rigorous screening for infectious diseases and genetic abnormalities. Donors signed the corresponding informed consent form during enrollment.	

<b>Reporting group values</b>	Tail		
Number of subjects	149		
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years arithmetic mean standard deviation	24.52 ± 5.97		
Gender categorical Units: Subjects			
Female	180		
Male	0		

## End points

### End points reporting groups

Reporting group title	control group
-----------------------	---------------

Reporting group description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:  
The control group receives the treatment on the 5th day after the cessation of hormonal contraceptive use and also receives additional FSH.

Reporting group title	study group
-----------------------	-------------

Reporting group description:

The used treatment is identical in both arms. The difference between the groups is the moment of beginning of the stimulation as well as the later administration of more FSH activity:  
The intervention group receives the treatment on the 7th day after the cessation of hormonal contraceptive use and does not receive additional FSH.

Subject analysis set title	Tail
----------------------------	------

Subject analysis set type	Per protocol
---------------------------	--------------

Subject analysis set description:

All oocyte donors included in the study were healthy women 18 - 32 years, with body mass index between 18 and 29 kg/m<sup>2</sup>, an antral follicle count (AFC) > 12, both ovaries present, with regular menstrual cycles and recruited according to the clinical and legal requirements of the Spanish Act for Assisted Human Reproduction: Reproductive Act (RD 9/2014) which includes: a psychological interview, gynecological examination and a rigorous screening for infectious diseases and genetic abnormalities. Donors signed the corresponding informed consent form during enrollment.

### Primary: number of MII oocytes retrieved

End point title	number of MII oocytes retrieved
-----------------	---------------------------------

End point description:

End point type	Primary
----------------	---------

End point timeframe:

This variable is assessed at the end of the patients' treatments, on the egg retrieval day.

End point values	control group	study group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	81	68		
Units: oocyte	13	9		

Attachments (see zip file)	MII oocyte number/Captura.PNG
----------------------------	-------------------------------

### Statistical analyses

Statistical analysis title	Wilcoxon rank sum test
----------------------------	------------------------

Statistical analysis description:

For the univariate statistical analysis of qualitative variables, the Chi - square test or Fisher's exact test will be used. For evaluation of normal distributions, the Shapiro - Wilk's test was performed. Depending on whether the variable has a normal distribution, the comparison between means was carried out using Student's t test or Wilcoxon rank sum test.  
Values of  $p < 0.05$  will be considered statistically significant.

Comparison groups	control group v study group
Number of subjects included in analysis	149
Analysis specification	Post-hoc
Analysis type	non-inferiority
P-value	< 0.05
Method	Wilcoxon (Mann-Whitney)
Parameter estimate	Mean difference (final values)



## Adverse events

---

### Adverse events information<sup>[1]</sup>

---

Timeframe for reporting adverse events:

between the start of the trial and the last visit of the last patient.

Assessment type	Systematic
-----------------	------------

---

### Dictionary used

---

Dictionary name	no specific dictiona
-----------------	----------------------

---

Dictionary version	1
--------------------	---

---

Frequency threshold for reporting non-serious adverse events: 0.05 %

---

### Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: Only approved medication was used in the trial. This medication is used frequently in ovarian stimulation protocols and it is well tolerated by the patients.

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported